retatrutide nombre comercial NO está disponible para uso médico ni comercial. Es un fármaco aún en investigación, desarrollado por Eli Lilly, que actúa sobre tres vías metabólicas (GLP-1, GIP y glucagón) y sigue en Retatrutida permite perder hasta 30

Why GLP-1 drugs and menopause could create a perfect storm for bone loss Bone loss can lead to osteoporosis, which causes bones to become porous, weaker and brittle, making them more likely to break, often in the hips, spine and wrists

It also promotes hepatic fat oxidation, meaning the liver breaks down stored fat more aggressively

[19] [20] These medications can occasionally mask or delay diagnosis of other gastrointestinal conditions

But these drugs aren't one-size-fits-all

doi: 10.1111/dom.14944

but if there's any advantage to being third in line, is that, it's active so much of the biomedical community is now activated to study the plausible role of GLP-1s and in different disease processes that we harvest a lot of these learnings as well